Severe Lactic Acidosis Due to Acute Intoxication by Emtricitabine/Tenofovir Alafenamide

Review began 10/15/2021

Review ended 10/23/2021

Published 10/24/2021

© Copyright 2021

Chaparala et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Swethapriya Chaparala¹, Rafael C. Da Silva¹, John Paul Papadopoulos¹

1. Internal Medicine, Piedmont Athens Regional Medical Center, Athens, USA

Corresponding author: Rafael C. Da Silva, dasilva.rafaelcarlos@gmail.com

Abstract

A 46-year-old female with a history of generalized anxiety disorder was admitted after intentional ingestion of an unknown amount of emtricitabine/tenofovir alafenamide (Descovy®) in a suicidal attempt. Patient was emergently intubated secondary to severe agitation and inability to protect airways. Patient developed severe lactic acidosis early in the admission, secondary as to a possible mitochondrial toxicity. Failed attempts to fluid resuscitation with Lactate Ringer®, eventually warranted to start the patient on norepinephrine infusion. Metabolic acidosis remained refractory to bicarbonate bolus and infusion. Hypothermia and hypoglycemia were corrected. Despite the initial approach, the patient remained acidotic, and the nephrology was consulted for emergent continuous renal replacement therapy (CRRT). After three days of intensive care unit stay and CRRT, the patient improved and was successfully decannulated. Her metabolic profile also showed remarkable improvement and the metabolic lactic acidosis resolved. The previous formulation of tenofovir with disoproxil fumarate is associated with severe lactic acidosis due to inhibition of mammalian mitochondrial DNA polymerase. Risk factors include liver cirrhosis, chronic kidney disease, hepatitis B and C coinfection, and metformin use. The new pharmaceutical formulation of tenofovir with alafenamide (TAF) has caused a significant decrease in the incidence of lactic acidosis. However, its real incidence and the usual plasma level to induce toxicity and mitochondrial dysfunction are unknown. The aim of this report is to highlight the risk of severe lactic acidosis with the use of TAF.

Categories: Emergency Medicine, Internal Medicine, Substance Use and Addiction

Keywords: toxicity, metabolic acidosis, lactic acidosis, intoxication, safety, emtricitabine, tenofovir, descovy

Introduction

Nucleotide/nucleoside reverse transcriptase inhibitors (NRTI) are the cornerstone in the treatment of human deficiency virus (HIV) infection. Mitochondrial dysfunction is a well-known complication associated with NRTI, remarkably with stavudine (d4T) and didanosine (ddI) [1-4]. It manifests with acute liver failure and severe lactic acidosis [5-7]. Tenofovir disoproxil fumarate (TDF) was the first nucleotide reverse transcriptase inhibitor with activity against HIV introduced in the United States in 2001 [8]. It was reported that the combination of TDF and ddI results in an increase in the serum concentration of ddI, which can augment the risk of toxicity [9,10]. However, severe lactic acidosis rarely happens with the use of tenofovir, given its lower affinity to mitochondrial DNA polymerase gamma [4,11]. In 2015, another formulation of tenofovir with alafenamide (TAF) showed better safety and tolerability profile with lower impact on renal function as well as in bone mineral density without decreased efficacy. TAF is more stable in the plasma and offers higher intracellular concentration in the lymphocytes cell population [12-14]. With the advent of TAF, a component of Descovy®, the incidence of severe lactic acidosis and other renal dysfunctions has decreased [13]. The rationale of this case report is to highlight the risk of severe lactic acidosis due to acute intoxication of TAF/emtricitabine (Descovy®) and its management.

Case Presentation

This is a 46-year-old female with a history of generalized anxiety disorder who presented to the emergency department four hours after intentional ingestion of tenofovir alafenamide/emtricitabine (Descovy®). The patient had no formal diagnosis of HIV or hepatitis B. Medications were obtained from a close relative. She complained of severe nausea and lower back pain. Denied concurrent use of alcohol or salicylates. On presentation to the emergency department, the patient was agitated, tachypneic and hemodynamically stable. Lab work showed increased anion gap metabolic acidosis with acute kidney injury. Toxicology work-up for salicylate and alcohols was negative. A urine drug screen was positive for benzodiazepines and methamphetamine. Complete blood count was unremarkable and urinalysis negative for ketones. After 10 hours, the patient evolved to clinical and laboratorial deterioration consistent with hemodynamic instability, sinus tachycardia of 120 bpm, tachypnea at a respiratory rate of 50 bpm, hypothermia of 93.2° F and cyanosis. Blood pressure dropped to 80/60 mmHg. Follow up chemistry panel showed worsening of lactic acidosis and hypoglycemia (Table 1).

How to cite this article

Chaparala S, Da Silva R C, Papadopoulos J (October 24, 2021) Severe Lactic Acidosis Due to Acute Intoxication by Emtricitabine/Tenofovir Alafenamide. Cureus 13(10): e19008. DOI 10.7759/cureus.19008

Laboratory	Initial results	Follow up results	Reference values
pH	7.04	< 6.77	7.35 – 7.45
Bicarbonate	11 mmol/L	4 mmol/L	22 – 28 mmol/L
Anion gap	24	39	10 – 12
Serum Creatinine	1.40 mg/dL	8 mg/dL	0.6 – 1.2 mg/dL
Lactic acid	10 mmol/L	27 mmol/L	< 2.3 mmol/L
PaO2		113 mm Hg	75 – 105 mm Hg
PvcO2		100 mm Hg	70 – 80 mm Hg

TABLE 1: Initial and follow up laboratory results.

PaO2: arterial partial pressure of oxygen. PvcO2: central venous partial pressure of oxygen.

Patient was emergently intubated and transferred to the ICU. The patient was placed on a norepinephrine infusion following a failed resuscitation attempt with intravenous fluids. The metabolic acidosis remained refractory to bicarbonate bolus and drip. Hypothermia and hypoglycemia were corrected. Despite the initial approach, the patient remained acidotic, and the nephrology was consulted for emergent continuous renal replacement therapy (CRRT). After three days of ICU and CRRT, the patient improved and was successfully decannulated. Her metabolic profile also showed remarkable improvement and the metabolic lactic acidosis resolved.

Discussion

TAF has a better safety and tolerability profile compared to TDF. However, it can be associated with severe lactic acidosis as demonstrated by this case report. In 2018, Alsunaid et al. reported a 65-year-old male status post-hematopoietic stem cell transplant due to multiple myeloma, who received treatment for hepatitis B with TAF and died of severe lactic acidosis [15]. Our report is the first case associated with severe lactic acidosis due to intentional acute intoxication by TAF/emtricitabine (Descovy®) in an attempt at suicide. Given the clinical presentation of the patient with dramatic clinical worsening with cyanosis, hypoglycemia, and hypothermia, we believed patient presumably painted a picture of mitochondrial dysfunction. Tenofovir is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ. Unfortunately, we were not able to precisely determine how much of the drug was ingested, neither the plasma concentration.

On the other hand, several studies demonstrated renal impairment with TDF including worsening creatinine clearance (CrCl) and proteinuria [13,14,16-19]. Interestingly, age older than 40 years was associated with a higher risk for renal abnormalities [20]. Additionally, concerns for permanent renal damage were suggested in patients taking highly active antiretroviral therapy (HAART) in this study published in 2009 [18]. Important to note, since 2003, several cases of fatal or severe lactic acidosis have been implicated with the use of TDF isolated [21-23] or in association especially with didanosine [9,24]. In addition, different associations including TDF and stavudine [5,24] as well as emtricitabine were also involved in episodes of lactic acidosis [25-27]. In two of those case reports, lactic acidosis was associated with metformin concomitantly with TDF. In one of them, continuous veno-venous hemofiltration was used successfully [25]. Lactic acid levels ranged between 5.3 to 14 mmol/l [24].

In 2015, TAF showed to be safer and better tolerated in comparison to TDF. To support this, no lactic acidosis was demonstrated by Triantos et al., who followed 107 patients with hepatitis B for five years [28]. Only in 2017, a case of acute tubular dysfunction due to mitochondrial toxicity was reported related to the use of TAF, however without severe lactic acidosis [29].

It is suggested that underlying conditions and combinations of drugs can precipitate lactic acidosis. This includes liver cirrhosis [21], coinfection with hepatitis C and B [21,23,26], diabetes mellitus [21,22,25], chronic kidney disease [11] and concurrent metformin use [24]. However, in 2012, Qayyum et al. reported a case of acute liver failure and severe lactic acidosis with TDF/FTC and efavirenz after three months of initiation of treatment in a 41-year-old male without previous liver disease [27]. Our patient had no comorbidities or risk factors that could precipitate lactic acidosis.

The overall treatment reported is to stop the medication, follow lactic acid levels in the plasma, and start on bicarbonate drip. In cases of refractory metabolic acidosis, hemodialysis is frequently used. Hemodialysis in our patient was thought to play a major role in the elimination of medication with resolution of lactic

acidosis. In the case reports listed, only four of the 14 patients survived after intoxication by tenofovir [5,9,11,15,16,21-25,27]. Our patient also had a favorable outcome without progression to chronic kidney disease. Likely, that was related to age and no comorbidities. Especially given the fatal nature of mitochondrial dysfunction, this warrants further studies.

Conclusions

Severe lactic acidosis is a rare and severe complication of tenofovir, especially with tenofovir disoproxil fumarate ingestion. Apparently, there is high mortality associated with this condition. Possible risk factors include liver cirrhosis, hepatitis B and C, chronic kidney disease, and concomitant use of metformin. With the advent of tenofovir alafenamide, the risk of severe lactic acidosis decreased. However, it is still possible to develop severe lactic acidosis with this formulation, especially in the setting of acute intoxication. The management is based on the treatment of metabolic acidosis with bicarbonate drip and hemodialysis for refractory cases. Patients under TAF should be closely followed and it is suggested that evaluation for suicidal ideation should be considered, however, further studies might be necessary to support it.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Bolhaar MG, Karstaedt AS: A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. *Clin Infect Dis*. 2007, 45:254-60. [10.1086/518976](#)
- Moyle G: Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. *Antivir Ther*. 2005, 10 Suppl 2:M47-52.
- Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT: Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. *J Infect Dis*. 2007, 196 Suppl 3:S449-56. [10.1086/521112](#)
- Venhoff N, Setzer B, Melkaoui K, Walker UA: Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. *Antivir Ther*. 2007, 12:1075-85.
- Giola M, Basilico C, Grossi P: Fatal lactic acidosis associated with tenofovir and abacavir. *Int J Infect Dis*. 2005, 9:228-9. [10.1016/j.ijid.2004.09.010](#)
- Lewis W, Day BJ, Copeland WC: Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. *Nat Rev Drug Discov*. 2003, 2:812-22. [10.1038/nrd1201](#)
- Patel V, Hedayati SS: Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy. *Nat Clin Pract Nephrol*. 2006, 2:109-14. [10.1038/ncpneph0102](#)
- Nelson MR, Katlama C, Montaner JS, et al.: The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. *AIDS*. 2007, 21:1273-81. [10.1097/QAD.0b013e3280b07b33](#)
- Guo Y, Fung HB: Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. *Pharmacotherapy*. 2004, 24:1089-94. [10.1592/phco.24.11.1089.36138](#)
- Masiá M, Gutiérrez F, Padilla S, Ramos JM, Pascual J: Severe toxicity associated with the combination of tenofovir and didanosine: case report and review. *Int J STD AIDS*. 2005, 16:646-8. [10.1258/0956462054944480](#)
- Murphy MD, O'Hearn M, Chou S: Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. *Clin Infect Dis*. 2003, 36:1082-5. [10.1086/368313](#)
- Antela A, Aguiar C, Compston J, et al.: The role of tenofovir alafenamide in future HIV management. *HIV Med*. 2016, 17:4-16. [10.1111/hiv.12401](#)
- Chan L, Asriel B, Eaton EF, Wyatt CM: Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. *Curr Opin Nephrol Hypertens*. 2018, 27:102-12. [10.1097/MNH.0000000000000392](#)
- Gupta SK, Post FA, Arribas JR, et al.: Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. *AIDS*. 2019, 33:1455-65. [10.1097/QAD.0000000000002223](#)
- Alsunaid SR, Ashraf H, Soubani AO: Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. *Transpl Infect Dis*. 2018, 20:e12960. [10.1111/tid.12960](#)
- Lee M, Eyer F, Felgenhauer N, Klinker HH, Spinner CD: Overdose of dolutegravir in combination with tenofovir disoproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient. *AIDS Res Ther*. 2015, 12:18. [10.1186/s12981-015-0054-y](#)
- Hansen AB, Mathiesen S, Gerstoft J: Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. *Scand J Infect Dis*. 2004, 36:389-92. [10.1080/00365540410027157](#)
- Izzedine H, Harris M, Perazella MA: The nephrotoxic effects of HAART. *Nat Rev Nephrol*. 2009, 5:563-73. [10.1038/nrneph.2009.142](#)
- Tang EC, Vittinghoff E, Anderson PL, et al.: Changes in kidney function associated with daily tenofovir

- disoproxil fumarate/emtricitabine for HIV preexposure prophylaxis use in the United States Demonstration Project. *J Acquir Immune Defic Syndr*. 2018, 77:193-8. [10.1097/QAI.0000000000001566](https://doi.org/10.1097/QAI.0000000000001566)
20. Touzard Romo F, Smeaton LM, Campbell TB, et al.: Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). *HIV Clin Trials*. 2014, 15:246-60. [10.1310/hct1506-246](https://doi.org/10.1310/hct1506-246)
21. Jung TY, Jun DW, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS: Fatal lactic acidosis in hepatitis B virus-associated decompensated cirrhosis treated with tenofovir: a case report. *Medicine (Baltimore)*. 2017, 96:e7133. [10.1097/MD.00000000000007133](https://doi.org/10.1097/MD.00000000000007133)
22. Kumar R, Agrawal S: Rapid onset of fatal lactic acidosis complicating tenofovir therapy in a diabetic patient with cirrhosis: a cautionary tale. *J Clin Exp Hepatol*. 2017, 7:80-1. [10.1016/j.jceh.2016.08.010](https://doi.org/10.1016/j.jceh.2016.08.010)
23. Ying Y, Hu YK, Jin JL, Zhang JM, Zhang WH, Huang YX: Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B. *BMC Gastroenterol*. 2018, 18:45. [10.1186/s12876-018-0773-3](https://doi.org/10.1186/s12876-018-0773-3)
24. Ortiz-Brizuela E, Pérez-Patrigeon S, Recillas-Gispert C, Gómez-Pérez FJ: Lactic acidosis complicating metformin and non-nucleoside reverse transcriptase inhibitor combination therapy: a smoldering threat in the post-HAART era. *Rev Invest Clin*. 2015, 67:273-4.
25. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P: Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. *J Ren Care*. 2011, 37:25-9. [10.1111/j.1755-6686.2011.00209.x](https://doi.org/10.1111/j.1755-6686.2011.00209.x)
26. Hashim H, Sahari NS, Sazlly Lim SM, Hoo FK: Fatal tenofovir-associated lactic acidosis: a case report. *Iran Red Crescent Med J*. 2015, 17:e19546. [10.5812/ircmj.19546](https://doi.org/10.5812/ircmj.19546)
27. Qayyum S, Dong H, Kovacic D, Sohail S, Waters B, Thornton C, Corbett CE: Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure. *Curr Drug Saf*. 2012, 7:391-3. [10.2174/157488612805076534](https://doi.org/10.2174/157488612805076534)
28. Triantos C, Kalafateli M, Aggeletopoulou I, et al.: Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. *Eur J Gastroenterol Hepatol*. 2017, 29:998-1003. [10.1097/MEG.0000000000000924](https://doi.org/10.1097/MEG.0000000000000924)
29. Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG: Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. *Medicine (Baltimore)*. 2017, 96:e8046. [10.1097/MD.00000000000008046](https://doi.org/10.1097/MD.00000000000008046)